Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, Milano, 20138, Italy.
Unit of Cardiovascular Aging, Centro Cardiologico Monzino IRCCS, Milano, 20138, Italy.
Mol Med. 2024 Sep 27;30(1):161. doi: 10.1186/s10020-024-00939-z.
The pathophysiological mechanisms of cardiovascular disease and microvascular complications in diabetes have been extensively studied, but effective methods of prevention and treatment are still lacking. In recent years, DNA methylation, histone modifications, and non-coding RNAs have arisen as possible mechanisms involved in the development, maintenance, and progression of micro- and macro-vascular complications of diabetes. Epigenetic changes have the characteristic of being heritable or deletable. For this reason, they are now being studied as a therapeutic target for the treatment of diabetes and the prevention or for slowing down its complications, aiming to alleviate the personal and social burden of the disease.This review addresses current knowledge of the pathophysiological links between diabetes and cardiovascular complications, focusing on the role of epigenetic modifications, including DNA methylation and histone modifications. In addition, although the treatment of complications of diabetes with "epidrugs" is still far from being a reality and faces several challenges, we present the most promising molecules and approaches in this field.
糖尿病心血管疾病和微血管并发症的病理生理机制已经得到了广泛的研究,但仍然缺乏有效的预防和治疗方法。近年来,DNA 甲基化、组蛋白修饰和非编码 RNA 被认为是糖尿病微血管和大血管并发症发生、维持和进展中涉及的可能机制。表观遗传变化具有遗传或可删除的特征。因此,它们现在被作为治疗糖尿病及其并发症的治疗靶点进行研究,旨在减轻疾病给个人和社会带来的负担。
这篇综述讨论了糖尿病与心血管并发症之间的病理生理联系的最新知识,重点介绍了表观遗传修饰(包括 DNA 甲基化和组蛋白修饰)的作用。此外,尽管用“epidrugs”治疗糖尿病并发症还远未成为现实,并面临着许多挑战,但我们在这一领域提出了最有前途的分子和方法。